



Eurofins acquires MET Laboratories, Inc.

11 January 2018

Eurofins Scientific (EUFI.PA), a global leader in testing, announces that it has acquired MET Laboratories, Inc., (“MET”), a US leader in testing, certification and compliance solutions for electrical products.

MET is a service leader in testing and certification for medical devices, household appliances, automotive and aerospace products. MET ensures that its customer’s products or equipment comply with government, regulatory, and industry safety standards to protect populations and the workplace from potential risks associated with use. MET employs 200 people in its operations in the US, China, Taiwan and Korea.

MET Labs has provided the global marketplace with diversified testing, certification, and compliance solutions for 60 years. In 1989, MET became the first Nationally Recognized Testing Laboratory (NRTL) approved to certify for product safety to over 200 UL standard categories and is trusted by manufacturers worldwide for fast market access. MET is the last major NRTL to become part of a global testing organization.

Comment from **Rob Frier**, President of MET Labs: “Joining the Eurofins network was a natural progression for MET Labs and provides major growth opportunities for our business and extended services for our clients. With the global network and backing of one of the world’s leading testing and certification organizations, MET’s customers will benefit from enhanced service offerings and innovation. The MET brand will continue to represent the highest level of competence and integrity”.

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agrosience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities

around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

MET Laboratories, Inc. – a global leader in electrical products testing – www.metlabs.com

MET is a global service leader for product approvals and regulatory certification of electrical products. In 1989, MET broke the UL monopoly for product safety testing and certification in the United States. With global facilities, international accreditations and 60 years of experience, today MET provides electrical product market access for its customers, worldwide.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.